Global Analysis of Ebola Disease

Global Analysis of Ebola Disease

Expenditure on Prevention and Containment to Soar towards $5.9 Billion by End of 2016

RELEASE DATE
18-Nov-2014
REGION
North America
Research Code: NED3-01-00-00-00
SKU: LS00132-NA-MR_16973
AvailableYesPDF Download

$2,450.00

Special Price $1,837.50 save 25 %

In stock
SKU
LS00132-NA-MR_16973

$2,450.00

$1,837.50save 25 %

DownloadLink
ENQUIRE NOW

Description

This market insight provides a first-of-its-kind analysis of market sizing and revenue forecasts through 2016 for the prevalent Ebola virus. The number of people infected nears 10,000 globally, and the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have deemed this the worst outbreak due to the death toll nearing 5,000. The Ebola market is segmented by diagnostics and pharmaceuticals, and the diagnostics market includes both molecular methods and immunodiagnostics tests, of which a 2-year potential-revenue forecast is provided. Molecular methods will see wide adoption for the specificity, sensitivity, and rapidity of the tests. Competitive landscape and companies to watch chapters are provided.

Table of Contents

Key Findings

What is Ebola?

Timeline of Key Events

Scope and Segmentation

Key Questions This Study Will Answer

CEO’s Perspective

Spread of Ebola

Methodology, Assumptions, and Definitions

Methodology, Assumptions, and Definitions (continued)

Methodology, Assumptions, and Definitions (continued)

Methodology, Assumptions, and Definitions (continued)

Projected Ebola Prevalence (Global)

Ebola Market for Molecular Tests (Global)

Ebola Market for Immunodiagnostic Tests (Global)

Global Expenditure Forecast by Mild Cases of Ebola

Global Expenditure Forecast by Severe Cases of Ebola

Global Expenditure Forecast Comparing Mild and Severe Ebola Cases

Competitive Landscape for Pipeline Vaccines and Drugs

Competitive Landscape for Diagnostic Products

Ebola Diagnostics

Ebola Drugs and Vaccines

Legal Disclaimer

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

This market insight provides a first-of-its-kind analysis of market sizing and revenue forecasts through 2016 for the prevalent Ebola virus. The number of people infected nears 10,000 globally, and the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have deemed this the worst outbreak due to the death toll nearing 5,000. The Ebola market is segmented by diagnostics and pharmaceuticals, and the diagnostics market includes both molecular methods and immunodiagnostics tests, of which a 2-year potential-revenue forecast is provided. Molecular methods will see wide adoption for the specificity, sensitivity, and rapidity of the tests. Competitive landscape and companies to watch chapters are provided.
More Information
No Index Yes
Podcast No
Author Aish Vivekanadan
WIP Number NED3-01-00-00-00
Is Prebook No